By Exopharm Ltd
In this webinar, Dr Ian Dixon, Exopharm’s Managing Director and Founder, discusses three recent ASX announcements and answers questions in a Q&A facilitated by Paul Hart, Executive Director of Canary Capital.
The following ASX announcements are addressed:
01/04/2021 Preclinical Data from Osteoarthritis Animal Study
06/04/2021 Positive PLEXOVAL II Phase 1 Clinical Trial Results
06/04/2021 LEAP Technology- Advanced EV Medicines from Blood Components
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
